This ones a heck of a specualive investment but it seems that the institutions are willing to stomp up the cash to back it in the long term.

Heres the latest news from Killik stocbrokers on the company..........

MEDICAL MARKETING Joint Venture

We recently highlighted Medical Marketing (MMG) as worthy of attention. The company, in which I have a personal share holding, has this morning announced the formation of a joint venture, Genvax, to develop a novel DNA vaccine platform technology.

Human trials have been underway since 2001 in areas such as Lymphoma and Myeloma but the technology has broad applications in cancer, viral and bacterial infections (hence the term platform). The technology works on boosting the immune system by teaching it to identify hard to recognise cancer proteins as foreign and destroy them. Early results from the 25 patient trial in lymphoma are encouraging and evaluation of the result is expected by March 2005. Successful results should mean big pharmaceutical groups will start to take financial and commercial interests around that time.

This looks to be the first of a series of announcements due from Medical Marketing as it has a range of predominantly cancer trials moving into the clinical stage. (news flow could push the price higher)

The stock has made good progress in recent sessions up to the mid-80p level where the company is valued at just under 40 million. ENDS.

Please DYOR

cheers GF.

News just in. Check it out everyone!!

Medical Marketing Int'l Group PLC
22 March 2005


For Immediate Release 22 March 2005


MMI ANNOUNCES CANCER VACCINES UPDATE


Medical Marketing International Group plc (LSE:MMG), the Cambridge, UK-based
pharmaceutical development company announces progress on its vaccine biobaby
Genvax.

Investor update on the status of clinical studies using the DNA fusion
gene technology.

Conclusion of worldwide exclusive licence from Cancer Research
Technology Limited to commercialise the DNA fusion gene technology.

MMI investment in Genvax Ltd, increasing its shareholding to 58%.

Clinical trials

Professor Freda Stevenson, Professor of Immunology at the University of
Southampton, presented on the use of DNA fusion gene vaccines against cancer,
including preclinical developments and clinical testing, at the second Annual
DNA Vaccines Forum, London on 18th March 2005. The presented case-study included
an overview of the fusion gene concept and the clinical testing of the DNA
fusion gene vaccines against lymphoma; the first in a series of human clinical
trials using novel vaccines that use tetanus toxin to boost the immune response
against cancer.

The trials to-date have been funded by major cancer charities including The
Leukaemia Research Fund (LRF) and Cancer Research UK. This first clinical trial
was a dose escalation study involving 25 patients with follicular lymphoma, a
cancer of the lymph glands. Patients were recruited to the trial between 2001
and 2004. A majority of patients have shown an immunological response to the
vaccine. Side effects include mild-flu like symptoms, however no safety or
tolerability issues have been reported. The full results of this study will be
reported by Cancer Research UK and LRF.

In addition to the lymphoma clinical trial, two pilot clinical trials in
patients with myeloma (cancer of the bone marrow) are ongoing. At the University
of Southampton, the DNA fusion gene vaccine technology is being evaluated in a
clinical trial targeting prostate cancer. A further clinical trial, funded by
Cancer Research UK, is planned for later this year with vaccines targeted to
colon cancer and other solid tumours such as lung or stomach cancer (tumours
that express the cancer antigen CEA).

Licence

Genvax announces that it has concluded an exclusive worldwide licence with
Cancer Research Technology Limited (CRT), the specialist oncology technology
transfer and development company, for the commercialisation rights to the novel
vaccines that use immunostimulants, including tetanus toxin, to boost the immune
response. The vaccines were invented by Prof. Stevenson and her world-class
research team at the University of Southampton.

Investment

MMI will make a further investment in Genvax (from within existing budgets,
conditional on certain commercial milestones being achieved) to support the
ongoing commercial development of the cancer therapies based on this DNA vaccine
technology. As a result of this investment, MMI's stake in Genvax will increase
from 50% to 58%. This new investment will be used by Genvax to progress the
commercial development of the cancer therapies, and will include:

The development of the core technology at the University of Southampton
under the direction of Professor Freda Stevenson.

Clinical development of commercial vaccine constructs under the direction
of Dr Christian Ottensmeier.

Funding will also support the development of the manufacturing process for
the DNA vaccines at the National Blood Service GMP facility in Bristol.

The investment will also support the maintenance and continued prosecution
of the patent portfolio surrounding the use of immunostimulants in DNA
vaccines, including tetanus toxin.

Commenting on these announcements, David Best, Chairman of MMI Group and Genvax,
said 'Cancer is now the main cause of premature death in the western world. By
working with the major cancer charities, the world class research team at the
University of Southampton and the National Blood Service, together we now have
the potential to improve the lives of patients with cancer and to keep the UK at
the forefront of medicine'.


For further information, please contact:
David Best - Executive Chairman
MMI Group Tel: +44 (0)1223 477677

www.mmigroup.co.uk


Lisa Baderoon/Rebecca Skye Dietrich
Buchanan Communications Tel: +44 (0)20 7466 5000

lisab@buchanan.uk.com

duplicated rns removed

Annoucement out now.. right on Q...

price drops after a sudden rise strange to me oh well.

mmmmm well knowing nothing about the treatment of cancer, it didn't make that great a read to me and has done FA for the sp.

MS

Well it looks okay to me, am I missing something?

License perhaps??

Not yet it seems..........

Down she goes....................................

Another bloodbath?

Not really it seems

Bloddy shite.

MS

Seems to be holding at 170ish at the mo, and in come some buyers.

Not too bad.

MM's overreaction as usual similar to Septs news.

Pass the Valium.
MS

pressed the wrong buttons...

MM's trying to get peoples to sell at 170p and they succeeded for a while but the big buyers are back and pushing up the price to near high of the day.

Excellent news. Should get some rave right ups in the papers and fincial press this week.

cheers GF.

Short term speculators out, buyers returning in strength and I can understand why. Dont think many have realised the impications of the news. Please read the AFX announcement.

Cheers GF.

Just hit 200p offer!!!!

GF, Mitzy

Luv you.

MS

He He,lovely just lovely.

cheers GF.

I must admit I bought in 5 mins before the Rns at 186p and then it fell to 170p within 5 mins.. but hey its all academic now as its reached my 210p level I predicted.Just imagine a vaccine for cancer within 2 years..off shopping now..!

Some have missed the massive impications of this..............

Medical Marketing to raise stake in Genvax to 58 pct from 50 pct
AFX


LONDON (AFX) - Medical Marketing International Group PLC said it will raise its stake in Genvax to 58 pct from 50 pct and that Genvax will use the new investment to help the commercial development of its cancer therapies.

Genvax also said it concluded an exclusive worldwide licence withCancer Research Technology Ltd to commercialise DNA fusion gene technology.

newsdesk@afxnews.com

jc

cheers GF.